Lilly Asia Ventures
Chinese drug developer Abbisko files for HK IPO
PE-backed Abbisko Therapeutics, which focuses on the discovery and development of innovative and differentiated small molecule oncology therapies, has filed for a Hong Kong IPO.
Deal focus: NiKang pursues hard-to-drug targets
With big pharma scaling back early-stage discovery, CBC Group is keen to incubate biotech start-ups developing drugs from scratch. NiKang Therapeutics is the first to secure wider investor attention
Lilly Asia leads $90m round for China's Duality Biologics
Lilly Asia Ventures has led a $90 million Series B round for Duality Biologics, a Chinese developer of oncology and autoimmune drugs.
Loyal Valley leads Series B extension for China's Edigene
Loyal Valley Capital has led a RMB400 million ($62 million) Series B extension for EdiGene, a China-based biotech company that uses genome editing technologies to accelerate drug discovery.
China's Connect Biopharma gains 8% on debut after $191m US IPO
Connect Biopharma, a China-headquartered drug developer specializing in treatments for T cell-driven inflammatory diseases, gained 8.8% on debut following a $191.3 million US IPO.
China’s Regor Therapeutics raises $90m Series B
Lilly Asia Ventures (LAV) has led a $90 million Series B round for Regor Therapeutics, a Chinese drug developer specializing in bioinformatics.
China cancer screening business gains on Hong Kong debut
New Horizon Health, a China-based and venture capital-backed cancer early screening company, rose 215% on its trading debut following a HK$2 billion ($258 million) Hong Kong IPO.
Lilly Asia Ventures raises $1.35b for healthcare funds
Lilly Asia Ventures (LAV) has raised $1.35 billion for its latest healthcare fund, having introduced a $450 million opportunity vehicle that sits alongside a core pool of $900 million.
Carlyle leads $123m Series D for China's Abbisko
The Carlyle Group - investing through its Asia growth fund - has led a $123 million Series D round for Chinese cancer-focused biotech developer Abbisko Therapeutics.
LAV, Arch lead $100m round for China's SciNeuro
SciNeuro Pharmaceuticals, a China and US-based drug developer specializing in treatments for central nervous system (CNS) disorders, has announced its formal launch with a $100 million funding round.
Chinese vision therapy start-up Elumninex raises $50m
Chinese eye disease specialist Elumninex Biosciences has raised a $50 million Series A round led by GL Ventures, Lilly Asia Ventures (LAV), and Quan Capital.
China's CARsgen raises $186m Series C
Chinese biotech player CARsgen Therapeutics has raised $186 million in Series C funding led by Loyal Valley Capital.
China biotech player Gracell raises $100m Series C
Wellington Management, OrbiMed and Morningside Ventures have led a $100 million Series C round for Gracell Biotechnologies, a China-based developer of cancer treatments.
3H Health leads $67m Series B for China's EdiGene
China’s 3H Health Investment has led a RMB450 million ($67 million) Series B round for local genetics-based drug discovery and therapeutics developer EdiGene.
COVID-19 flexibility can exacerbate PE gender issues
Working from home has been a mixed experience for women in private equity, with greater flexibility counterbalanced by heightened feelings of isolation in environments that are already dominated by men.
RA Capital leads round for China's Connect Biopharma
Connect Biopharma, a drug developer based in China and the US, has raised $115 million in Series C funding led by RA Capital Management.
China drug developer Dizal raises $100m
Chinese drug developer Dizal Pharmaceuticals has raised a $100 million round led by Lilly Asia Ventures, with participation from Sequoia Capital, Trinity Innovation Fund, and Wuxi NewForce Fund.
China’s VC-backed CanSino raises $748m in Star Market IPO
Chinese vaccine developer CanSino Biologics, which counts Lily Asia Ventures (LAV) and Qiming Venture Partners among its investors, has raised RMB5.2 billion ($748 million) in an IPO on Shanghai’s Star Market.
Healthcare investors warn Asia unprepared for winter - AVCJ Forum
Private equity professionals focusing on healthcare told the AVCJ Southeast Asia Virtual Forum that COVID-19’s full impact has yet to be understood. The private and public sectors will need to work together to see out a difficult year.
China cancer test kit provider gets $30m Series E
New Horizon Health, a China-based manufacturer of cancer testing kits for use at home, has raised $30 million in a Series E round of funding led by Rock Springs Capital.
China's Burning Rock soars on debut after $222m US IPO
Burning Rock Biotech, a venture capital-backed, China-based provider of genetic testing services used in cancer diagnosis, rose 49% on its trading debut following a $222.8 million US IPO.
China’s Burning Rock Biotech files for US IPO
Burning Rock Biotech, a venture capital-backed, China-based provider of genetic testing services used in cancer diagnosis, has filed for an IPO in the US.
Temasek leads $70m Series C for China's Abbisko Therapeutics
Temasek Holdings has led a $70 million Series C round for Chinese drug developer Abbisko Therapeutics.
Chinese drug developer RemeGen raises $100m
RemeGen, a Chinese drug developer, has raised a $100 million round led by Lilly Asia Ventures and Lake Bleu Capital.